TERAWULF INC. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that TERAWULF INC. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $168.46M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $140.05M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $69.23M | Feb 27, 2026 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $13.43M | Mar 3, 2021 |
| FY2020 | Dec 31, 2019 | $17.62M | Mar 3, 2021 |
| FY2019 | Dec 31, 2018 | $18.21M | Mar 3, 2020 |
| FY2018 | Dec 31, 2017 | $17.24M | Mar 1, 2019 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $66.05M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $69.79M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $37.03M | Feb 27, 2026 |
| FY2023 | Dec 31, 2022 | $3.95M | Mar 20, 2024 |
| FY2020 | Dec 31, 2020 | $3.91M | Mar 3, 2021 |
| FY2020 | Dec 31, 2019 | $5.40M | Mar 3, 2021 |
| FY2019 | Dec 31, 2018 | $6.25M | Mar 3, 2020 |
| FY2018 | Dec 31, 2017 | $5.73M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $6.24M | Mar 2, 2018 |
| FY2016 | Dec 31, 2015 | $6.14M | Mar 3, 2017 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($661.42M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($72.42M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | ($73.42M) | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | ($90.79M) | Mar 3, 2025 |
| FY2021 | Dec 31, 2021 | ($94.01M) | Mar 31, 2022 |
| FY2021 | Mar 31, 2021 | ($1.68M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2020 | ($439.3K) | Mar 3, 2021 |
| FY2020 | Dec 31, 2019 | ($813.6K) | Mar 3, 2021 |
| FY2019 | Dec 31, 2018 | $139.5K | Mar 3, 2020 |
| FY2018 | Dec 31, 2017 | ($226.1K) | Mar 1, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($186.21M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($76.22M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | ($29.42M) | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | ($43.75M) | Mar 3, 2025 |
| FY2021 | Dec 31, 2021 | ($41.72M) | Mar 31, 2022 |
| FY2021 | Mar 31, 2021 | ($1.68M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2020 | ($1.79M) | Mar 3, 2021 |
| FY2020 | Dec 31, 2019 | ($956.7K) | Mar 3, 2021 |
| FY2019 | Dec 31, 2018 | $225.8K | Mar 3, 2020 |
| FY2018 | Dec 31, 2017 | ($464.6K) | Mar 1, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | $671.5K | Mar 3, 2021 |
| FY2020 | Dec 31, 2019 | $870.3K | Mar 3, 2021 |
| FY2019 | Dec 31, 2018 | $677.2K | Mar 3, 2020 |
| FY2018 | Dec 31, 2017 | $688.7K | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $647.1K | Mar 2, 2018 |
| FY2016 | Dec 31, 2015 | $660.4K | Mar 3, 2017 |
| FY2015 | Dec 31, 2014 | $665.0K | Mar 2, 2016 |
| FY2014 | Dec 31, 2013 | $649.3K | Mar 5, 2015 |
| FY2013 | Dec 31, 2012 | $629.8K | Mar 5, 2014 |
| FY2012 | Dec 31, 2011 | $512.3K | Mar 5, 2013 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $22.77M | Mar 31, 2023 |
| FY2021 | Dec 31, 2021 | $23.51M | Mar 31, 2022 |
| FY2021 | Mar 31, 2021 | $246.0K | Mar 31, 2022 |
| FY2020 | Dec 31, 2020 | $5.02M | Mar 3, 2021 |
| FY2020 | Dec 31, 2019 | $5.48M | Mar 3, 2021 |
| FY2019 | Dec 31, 2018 | $5.35M | Mar 3, 2020 |
| FY2018 | Dec 31, 2017 | $5.51M | Mar 1, 2019 |
| FY2017 | Dec 31, 2016 | $5.61M | Mar 2, 2018 |
| FY2016 | Dec 31, 2015 | $5.26M | Mar 3, 2017 |
| FY2015 | Dec 31, 2014 | $5.12M | Mar 2, 2016 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($123.18M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($24.42M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $4.26M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | ($34.07M) | Mar 3, 2025 |
| FY2022 | Sep 30, 2022 | ($29.61M) | Mar 31, 2023 |
| FY2022 | Jun 30, 2022 | ($23.54M) | Mar 31, 2023 |
| FY2022 | Mar 31, 2022 | ($15.25M) | Mar 31, 2023 |
| FY2021 | Dec 31, 2021 | ($24.10M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2020 | ($398.8K) | Mar 3, 2021 |
| FY2020 | Dec 31, 2019 | ($477.0K) | Mar 3, 2021 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.06B | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $267.94M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $75.17M | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | $61.12M | Mar 3, 2025 |
| FY2022 | Jun 30, 2022 | $45.47M | Mar 31, 2023 |
| FY2022 | Mar 31, 2022 | $27.75M | Mar 31, 2023 |
| FY2021 | Dec 31, 2021 | $85.37M | Mar 31, 2022 |
| FY2021 | Mar 31, 2021 | $23.70M | Mar 31, 2022 |
| FY2020 | Dec 31, 2020 | $149.9K | Mar 3, 2021 |
| FY2020 | Dec 31, 2019 | $478.4K | Mar 3, 2021 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.56B | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $787.51M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $378.11M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $317.69M | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | $264.91M | Mar 31, 2023 |
| FY2021 | Mar 31, 2021 | $30.01M | Mar 31, 2022 |
| FY2020 | Dec 31, 2020 | $15.44M | Mar 3, 2021 |
| FY2020 | Dec 31, 2019 | $16.88M | Mar 3, 2021 |
| FY2019 | Dec 31, 2018 | $17.42M | Mar 3, 2020 |
| FY2018 | Dec 31, 2017 | $16.92M | Mar 1, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $6.42B | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $543.07M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $155.62M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $199.93M | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | $141.73M | Mar 31, 2023 |
| FY2021 | Mar 31, 2021 | $1.74M | Mar 31, 2022 |
| FY2020 | Dec 31, 2020 | $3.60M | Mar 3, 2021 |
| FY2020 | Dec 31, 2019 | $4.62M | Mar 3, 2021 |
| FY2019 | Dec 31, 2018 | $4.31M | Mar 3, 2020 |
| FY2018 | Dec 31, 2017 | $3.97M | Mar 1, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $140.45M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $244.45M | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | $222.49M | Feb 27, 2026 |
| FY2025 | Dec 31, 2022 | $117.75M | Feb 27, 2026 |
| FY2024 | Dec 31, 2021 | $123.18M | Mar 3, 2025 |
| FY2021 | Mar 31, 2021 | $28.27M | Mar 31, 2022 |
| FY2022 | Feb 7, 2021 | $0 | Mar 31, 2023 |
| FY2020 | Dec 31, 2020 | $11.84M | Mar 3, 2021 |
| FY2020 | Dec 31, 2019 | $12.26M | Mar 3, 2021 |
| FY2020 | Dec 31, 2018 | $13.11M | Mar 3, 2021 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $55.46M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Feb 27, 2026 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($993.69M) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | ($332.28M) | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | ($259.90M) | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | ($186.47M) | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | ($95.68M) | Mar 31, 2023 |
| FY2021 | Mar 31, 2021 | ($1.68M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2020 | $8.90M | Mar 3, 2021 |
| FY2020 | Dec 31, 2019 | $9.34M | Mar 3, 2021 |
| FY2019 | Dec 31, 2018 | $10.19M | Mar 3, 2020 |
| FY2018 | Dec 31, 2017 | $10.05M | Mar 1, 2019 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.27B | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $274.07M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $54.44M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $1.28M | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | $43.45M | Mar 31, 2023 |
| FY2021 | Mar 31, 2021 | $6.30M | Mar 31, 2022 |
| FY2020 | Dec 31, 2020 | $3.69M | Mar 3, 2021 |
| FY2020 | Dec 31, 2019 | $963.6K | Mar 3, 2021 |
| FY2019 | Dec 31, 2018 | $1.62M | Mar 3, 2020 |
| FY2018 | Dec 31, 2017 | $929.7K | Mar 1, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $3.10B | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | $0 | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | $123.52M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | $124.91M | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | $94.63M | Mar 31, 2023 |
| FY2019 | Dec 31, 2019 | $2.92M | Mar 3, 2020 |
| FY2018 | Dec 31, 2018 | $3.06M | Mar 1, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Mar 3, 2025 |
| FY2021 | Dec 31, 2021 | (1) | Mar 31, 2022 |
| FY2021 | Mar 31, 2021 | 0 | Mar 31, 2022 |
| FY2020 | Dec 31, 2020 | 0 | Mar 3, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Mar 3, 2021 |
| FY2019 | Dec 31, 2018 | 0 | Mar 3, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Mar 1, 2019 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (1) | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 27, 2026 |
| FY2025 | Dec 31, 2023 | 0 | Feb 27, 2026 |
| FY2024 | Dec 31, 2022 | 0 | Mar 3, 2025 |
| FY2021 | Dec 31, 2021 | (1) | Mar 31, 2022 |
| FY2021 | Mar 31, 2021 | 0 | Mar 31, 2022 |
| FY2020 | Dec 31, 2020 | 0 | Mar 3, 2021 |
| FY2020 | Dec 31, 2019 | 0 | Mar 3, 2021 |
| FY2019 | Dec 31, 2018 | 0 | Mar 3, 2020 |
| FY2018 | Dec 31, 2017 | 0 | Mar 1, 2019 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 420.07M | Feb 27, 2026 |
| FY2025 | Dec 31, 2024 | 385.65M | Feb 27, 2026 |
| FY2024 | Dec 31, 2023 | 276.73M | Mar 3, 2025 |
| FY2023 | Dec 31, 2022 | 145.49M | Mar 20, 2024 |
| FY2022 | Dec 31, 2021 | 99.98M | Mar 31, 2023 |
| FY2021 | Mar 31, 2021 | 50.00M | Mar 31, 2022 |
| FY2020 | Dec 31, 2020 | 1.98M | Mar 3, 2021 |
| FY2020 | Dec 31, 2019 | 1.98M | Mar 3, 2021 |
| FY2019 | Dec 31, 2018 | 1.98M | Mar 3, 2020 |
| FY2018 | Dec 31, 2017 | 1.98M | Mar 1, 2019 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2012 | Dec 31, 2012 | $2.00M | Mar 5, 2013 |